16.73
3.02 (22.03%)
| Penutupan Terdahulu | 13.71 |
| Buka | 16.87 |
| Jumlah Dagangan | 7,588,137 |
| Purata Dagangan (3B) | 1,922,640 |
| Modal Pasaran | 1,207,376,128 |
| Harga / Pendapatan (P/E TTM) | 14.68 |
| Harga / Pendapatan (P/E Ke hadapan) | 58.14 |
| Harga / Jualan (P/S) | 98.47 |
| Harga / Buku (P/B) | 8.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2026 |
| EPS Cair (TTM) | -3.04 |
| Nisbah Semasa (MRQ) | 1.16 |
| Aliran Tunai Operasi (OCF TTM) | -142.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -102.50 M |
| Pulangan Atas Aset (ROA TTM) | -30.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Omeros Corporation | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.83 |
|
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.40% |
| % Dimiliki oleh Institusi | 47.30% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Kotler Kevin | 31 Dec 2025 | 905,635 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |